The largest Ebola outbreak in history has struck fear into the hearts of people around the world. While fewer than 3,000 people have been killed by the virus since it was discovered in 1976, the disease's virulence and deadliness, combined with the lack of a cure, inspire dread like almost no other.
We asked you what questions you had about Ebola and received more than 1,000 responses via social media. Here are answers to some of your most common questions and concerns.
What is Ebola?
"It is a highly infectious virus that can kill up to 90 percent of the people who catch it, causing terror among infected communities," Medecins Sans Frontieres says.
The Ebola virus causes viral hemorrhagic fever, which, according to the U.S. Centers for Disease Control and Prevention, refers to a group of viruses that affect multiple organ systems in the body and are often accompanied by bleeding.
The virus is named after the Ebola River in the Democratic Republic of Congo (formerly Zaire), where one of the first outbreaks occurred in 1976.
The World Health Organization says there are five different strains of the virus, named after the areas where they originated. Three of these have been associated with large outbreaks of hemorrhagic fever in Africa. Of Ebola's five subtypes, the Zaire strain -- the first to be identified -- is considered the most deadly. The WHO said preliminary tests on the Ebola virus in Guinea in March suggested that the outbreak there was this strain, though that has not been confirmed.
What are Ebola's symptoms?
Early symptoms include sudden onset of fever, weakness, muscle pain, headaches and a sore throat. These symptoms can appear two to 21 days after infection.
The WHO says these nonspecific early symptoms can be mistaken for signs of diseases such as malaria, typhoid fever, meningitis or even the plague.
MSF says some patients may also develop a rash, red eyes, hiccups, chest pains and difficulty breathing and swallowing.
The early symptoms progress to vomiting, diarrhea, impaired kidney and liver function and sometimes internal and external bleeding. CNN's Dr. Sanjay Gupta says that if a patient is going to die from Ebola, he or she usually does so within about 10 days.
Ebola can only be definitively confirmed by five different laboratory tests.
How is it treated? What about that experimental drug?
There are no specific approved treatments for Ebola. MSF says patients are isolated and then supported by health care workers.
"This consists of hydrating the patient, maintaining their oxygen status and blood pressure and treating them for any complicating infections," it says.
Two American missionary workers infected with Ebola were given an experimental drug called ZMapp, which seems to have saved their lives. The drug, developed by a San Diego firm, had never been tried before on humans, but it showed promise in small experiments on monkeys. The Americans who received it have since been declared healthy and discharged from Emory University Hospital in Atlanta.
ZMapp was also administered to three Liberian health care workers who contracted Ebola. At first, they showed "very positive signs of recovery," according to the Liberian Ministry of Health, but one has since died of the disease.
Why haven't other patients been given the experimental drug?
An ethics panel convened by the WHO concluded it is ethical to give experimental drugs during an outbreak as large as this one, but that doesn't mean it will happen.
Rolling out an untested drug during a massive outbreak would be very difficult, according to MSF. Experimental drugs are typically not mass-produced, and tracking the success of such a drug if used would require extra medical staff where resources are already scarce. ZMapp's maker says it has very few doses ready for patient use.
What about a vaccine?
There is currently no approved vaccination against Ebola.
At least one potential Ebola vaccine has been tested in healthy human volunteers, according to Thomas Geisbert, a leading researcher at the University of Texas Medical Branch. And last week, the NIH announced that a safety trial of another Ebola vaccine will start as early as September.
In March, the U.S. National Institutes of Health awarded a five-year, $28 million grant to establish a collaboration between researchers from 15 institutions who were working to fight Ebola.